Diagnoses of attention deficit hyperactivity disorder (ADHD) are rising rapidly in the U.K. More children and teenagers than ever are being referred for assessment and support, and families are often ...

Saffron is a spice that’s been used in cooking for thousands of years, but it’s popping up all over social media in recent ...

Otsuka Pharmaceutical announced that the FDA is reviewing investigational centanafadine -- a potential first-in-class ...

From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Garlic supplements can be beneficial for lowering high blood pressure and improving your gut microbiome, but there are some ...